Outreach-Based Long-Acting Injectable Buprenorphine

Outreach-Based Long-Acting Injectable Buprenorphine: A Viable Pathway to Closing OUD Treatment Gaps

Overdose deaths involving fentanyl increased by 45% from 2021 to 2022 in Washington State, disproportionately involving people experiencing houselessness, highlighting the urgent need to increase access to medications for opioid use disorder (MOUD) in this population. A multidisciplinary outreach team is successfully breaking down those barriers by offering field-based long-acting injectable buprenorphine (LAI-BUP) to people with opioid use disorder in outreach settings including permanent support housing sites. 

Field-based LAI-BUP injections offer a significant advantage to this population, providing a reliable and convenient long-acting option that increases sustained therapeutic OUD treatment and ultimately aiding in peoples’ continued success in housing.

Learn more and register

For trainings that indicate Continuing Education Units (CEUs) are available, contact your licensing or certification organization to verify that the credits will count toward the continuing education requirements.